|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:antidote
|
none specific
|
|
gptkbp:bannedIn
|
many countries
|
|
gptkbp:CASNumber
|
77-10-1
|
|
gptkbp:category
|
NMDA receptor antagonist
Hallucinogen
recreational drug
dissociative anesthetic
|
|
gptkbp:chemicalFormula
|
C17H25N
|
|
gptkbp:discoveredBy
|
gptkb:Parke-Davis
|
|
gptkbp:discoveredIn
|
1926
|
|
gptkbp:excretion
|
kidneys
|
|
gptkbp:fullName
|
gptkb:Phencyclidine
|
|
gptkbp:halfLife
|
7-46 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PCP
|
|
gptkbp:legalStatus
|
Class A drug (UK)
Schedule II controlled substance (US)
|
|
gptkbp:mainStreet
|
gptkb:Embue
gptkb:Angel_Dust
Ozone
Rocket Fuel
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
243.39 g/mol
|
|
gptkbp:originallyDevelopedAs
|
analgesic
|
|
gptkbp:overdoseSymptoms
|
high
|
|
gptkbp:relatedTo
|
gptkb:methoxetamine
gptkb:dextromethorphan
gptkb:ketamine
|
|
gptkbp:routeOfAdministration
|
smoked
ingested
injected
snorted
|
|
gptkbp:sideEffect
|
paranoia
numbness
coma
seizures
hallucinations
agitation
loss of coordination
violent behavior
delusions
|
|
gptkbp:toxicity
|
neurotoxic
|
|
gptkbp:treatmentForOverdose
|
supportive care
|
|
gptkbp:usedAs
|
recreational drug
dissociative drug
|
|
gptkbp:withdrawalSymptom
|
gptkb:depression
anxiety
craving
|
|
gptkbp:bfsParent
|
gptkb:Pneumocystis_pneumonia
gptkb:Precision_Castparts
|
|
gptkbp:bfsLayer
|
5
|